2015, issue 1: Impairments in gait, posture and complex movement control in rats modeling the multi-system, cholinergic-dopaminergic losses in Parkinson’s Disease / by Aaron Kucinski / featuring 192-IgG-SAP (Cat. #IT-01), Anti-ChAT-SAP (Cat. #IT-42) Society for Neuroscience Poster of the Year Award Veterinary Development of Substance P-Saporin (SP-SAP) Targeting Talk: Protocols and Dosage Targeting Tools: ZAP SrB Development …
The ZAP Sulforhodamine B (SrB; Cat. #KIT-SrB-Z) Development kit contains all of the materials needed to introduce a quantitative staining assay to your lab. Preferred by the National Cancer Institute for high-throughput drug screening, SrB quantitatively stains cellular proteins in an accurate and reproducible manner. Refined and honed over years of use in testing Saporin-conjugate …
Q: Our lab is getting ready to begin a project using one of your targeted toxins. We already did a preliminary experiment to try out the material, but we have a couple of questions before we start the larger project. First, do you have any protocols or references for injecting intrathecally? A: Thank you for …
The rate of fall of blood glucose determines the necessity of forebrain-projecting catecholaminergic neurons for male rat sympathoadrenal responses. Jokiaho AJ, Donovan CM, Watts AG. Diabetes 63(8):2854-2865, 2014. Different sets of glucosensors detect insulin-induced hypoglycemia depending on the onset rate. This detection controls the activation of sympathoadrenal counterregulatory responses (CRRs). Slow onset hypoglycemia, common with …
A groundbreaking pain therapeutic is poised for conditional approval in 2015 to treat bone cancer pain in dogs. The FDA has already approved Minor Use/Minor Species (MUMS) designation for the drug, providing extended market exclusivity to treat the >10,000 annual cases of canine bone cancer-related pain, and the ability to commercialize the drug as soon …
Veterinary Development of Substance P-Saporin (SP-SAP) Read More »
Congratulations to Dr. Kucinski as this year’s winner of the SfN Poster of the Year Award for the most interesting work presented using ATS products. You can read a summary of this work from Dr. Sarter’s lab in the cover article in this issue of Targeting Trends. Here is a small sample of the comments …
Targeting Article: Society for Neuroscience Poster of the Year Award Read More »
by Aaron Kucinski (Collaborators at University Michigan, Ann Arbor: K. Phillips, R. Albin, M. Sarter) In addition to the primary disease-defining symptoms that result from extensive loss of nigrostriatal dopaminergic neurons, approximately half of patients with Parkinson’s Disease (PD) suffer from postural instability, impairments in gait control and a propensity for falls. These symptoms have …